In October, when GSK agreed to a $2.2 billion settlement to resolve approximately 80,000 lawsuits | With a $2.2 billion ...

British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug.

LEONARDO MUNOZ/AFP via Getty Images. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy ...

In April 2020, the FDA requested that manufacturers cease selling Zantac and any generic alternatives. The complaint alleges that during the class period, defendants misrepresented the reasons ...

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

Valisure reported these results to the U.S. Food and Drug Administration (“FDA”) and to the public. In September and October 2019, GSK suspended its distribution of Zantac and initiated a ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline. It came as the boss of the London-listed firm cheered an “excellent ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

Operating profits dropped by 40% to £4 billion due to a £1.8 billion settlement following lawsuits linked to its former heartburn drug Zantac. GSK said it expects core operating profits to rise ...